ACAD
ACADIA Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · US
$28.04
+0.64%Aug 24, 2026, 07:01 UTC
The European Commission granted marketing authorization to Acadia Pharmaceuticals for DAYBU (trofinetide) as the first and only treatment for neurobehavioral symptoms of Rett syndrome in the European Union, for adults and pediatric patients aged five years and older.
Source:Aug 12, 2026, 19:04 UTC
ACADIA Pharmaceuticals outlined commercial expansion plans for its marketed therapies DAYBUE and NUPLAZID during a Canaccord Genuity-hosted discussion.
Source:Aug 4, 2026, 20:05 UTC
Acadia Pharmaceuticals reported its financial results for the second quarter ended June 30, 2026, with total revenue growing 17% year-over-year on an adjusted basis.
Jul 31, 2026, 00:00 UTC
Vistagen Therapeutics appointed Douglas J. Williamson, M.D. as a director, effective July 29, 2026, with stock option compensation and eligibility for the Director Compensation Plan.
Jun 26, 2026, 10:49 UTC
The CHMP of the EMA adopted a positive opinion recommending marketing authorization for DAYBU (trofinetide) for Rett syndrome in the EU.